ROBERT®: UK’s first paediatric trial concludes at The Children’s Trust

The Children’s Trust have successfully concluded the UK’s first paediatric trial of the ROBERT®, an innovative robotic rehabilitation device for upper and lower limb therapy. This trial marks a new path for paediatric neurorehabilitation.

Over three months, the ROBERT® device was integrated into the neurorehabilitation programmes at The Children’s Trust, supporting children and young people with brain injury.

“The trial demonstrated the device’s potential to reduce handling and facilitate an increase in repetition of movement, contributing to recovery outcomes through upper and lower limb mobilisation.”

ROBERT®, developed by Life Science Robotics and represented in the UK by Summit Medical and Scientific, has proven to be a versatile and effective addition to neurorehabilitation. It accommodates children and young people with varying levels of ability.

Physiotherapists and Occupational Therapists at The Children’s Trust reported that ROBERT® not only provided greater opportunities for mobilisation but also allowed them to focus on other critical aspects of care, thanks to its intuitive and efficient operation.

The Children’s Trust is now evaluating the trial data to explore the potential for robotic rehabilitation in paediatric settings. Thank you to the team at The Children’s Trust, and the children and families, who supported the UK’s first paediatric trial of this device.

To register your interest in a trial of the ROBERT®, please get in touch.

About the ROBERT®

Image provide by Life Science Robotics. Kulturnat, Industriens Hus, 15/10 2021. © Thomas Arnbo

ROBERT® is a robotic rehabilitation device, offering a complete and flexible solution for upper and lower limb therapy.

ROBERT® provides intensive rehabilitation for acute patients as early as possible, and can be used for upper or lower limb therapy either in-bed or seated with just one device.

Even severely impaired patients can be mobilised using ROBERT®, supporting a patient’s rehabilitation as soon as possible after their admission to hospital. Getting patients moving early and intensively is an important step towards optimal recovery and facilitating neuroplasticity.

Therapists first define the desired movement using ROBERT®, including Activities of Daily Living and Proprioceptive Neuromuscular Facilitation with seven degrees of freedom.

The ROBERT® then repeats the intensive therapy, offering tailored levels of resistance and support based on the patient’s ability.

Passive mobilisation is for completely immobilised patients, where ROBERT® carries out the exercise on the behalf of patients with reduced or no function. Active assistive mobilisation guides the patient through the exercise, and the patient’s function and strength determine the level of activity. Finally, active resistive mobilisation offers resistance against the patient’s movement.

ROBERT®’s assistive technology reduces the need for heavy and repetitive lifts, freeing resources for other aspects of clinical treatment and reducing the strain on the therapist. Clinicians can transport the device throughout their facility to each patient, and simply plug, attach, record and play using the intuitive interface. Patients can be set up and ready to go in as little as three minutes.

About Summit Medical and Scientific

Summit Medical and Scientific are passionate about the power of rehabilitation technology.

We represent clinical technology leaders Life Science Robotics, Hocoma, Motek and ddrobotec® to provide the total solution for rehabilitation in the UK. Our partners have developed innovative therapy devices using robotics, sensors and virtual reality for early and acute rehabilitation, gait and balance therapy, arm and hand therapy, body weight support and more. View all of our clinical solutions here.

Get in touch with Summit Medical and Scientific today to find out more about incorporating state-of-the-art rehabilitation technology into your practice.

You can also follow us on Facebook, Instagram, Twitter (X) and LinkedIn, and subscribe to our newsletter for the latest updates.